1. Introduction {#sec1}
===============

Colorectal cancer (CRC) is the third leading cause of cancer death for both men and women in the USA \[[@B1]\]. In Europe, CRC represents one of the primary causes of cancer deaths \[[@B2]\], and, in Asia, CRC is the fourth leading cause of mortality by cancer, and its incidence is increasing \[[@B3]\]. Epidemiological evidences have suggested that the risk of colorectal neoplasm is affected by multiple factors including a positive family history, excessive meat consumption, smoking status, and alcohol consumption, as well as genetic alterations, such as genetic polymorphisms \[[@B2]\].

However, the mechanism of colorectal carcinogenesis is still not fully understood. Compared with other complex diseases, CRC may be caused by both genetic and environmental factors \[[@B4]\]. Because well-recognized genetic predisposition syndromes account for less than 3% of CRC, low-penetrance genetic factors alone or in combination with environmental factors probably contribute to the development of CRC \[[@B5]\].

MicroRNAs (miRNAs) are a large class of small noncoding RNAs, which participate in various biological processes and may regulate tumor suppressor genes or oncogenes \[[@B6]\]. Single nucleotide polymorphisms (SNPs) in miRNAs may alter the expression, processing, and transcription of miRNAs and thus contribute to cancer development \[[@B7]\]. Recently, many epidemiological studies have demonstrated that some SNPs in the miRNA genes could alter miRNA expression and/or maturation and also be associated with the susceptibility and progression of cancer \[[@B8]\]. Rs2910164 in hsa-mir-146a locus resides at position +60 relative to the first nucleotide of the pre-miR-146a gene. The previous studies have shown that miR-146a plays an important role in cell proliferation and metastatic ability in cancers and the variation of miR-146a may be involved in carcinogenesis \[[@B9], [@B10]\]. MiR-196a2 includes two different mature miRNAs (miR-196a-5P and miR-196a-3P) and rs11614913 located in the mature sequence of miR-196a-3P. Rs11614913 could influence the expression levels of mature miR-196a and may have an impact on the expression of its target gene, which may play a role in regulating carcinogenesis \[[@B10]\]. It has been identified that rs3746444 is located in the stem region of the mir-499 gene. And several studies have identified miR-499 rs3746444 as a possible biomarker for some cancers \[[@B12]--[@B14]\]. Compared with other three genes, there were few studies of rs2292932 in miR-149 up to now. But the T allele in miR-149 might be masked by the presence of other unidentified causal genes involved in cancer development \[[@B15]\]. Furthermore, several Genome-wide association studies have reported that these four common SNPs may be associated with cancer risk \[[@B8]\]. However, results of these studies remain inconsistent. To provide a more precise estimate of the association of miRNA polymorphisms with CRC risk, we performed a meta-analysis on all eligible published case-control studies and evaluated the effect of the four SNPs on CRC risk.

2. Methods {#sec2}
==========

2.1. Publication Search {#sec2.1}
-----------------------

Relevant articles were independently searched by two authors (Wang M and Dai ZJ) in PubMed, Web of Science, and Chinese National Knowledge Infrastructure (CNKI). The keywords were as follows: colorectal cancer/colorectal carcinoma, microRNA 146a/149/196a2/499, and polymorphism/genotype/variant/SNP. All qualified studies prior to December 20, 2014, were included. The eligible literature must be published in English or Chinese. Furthermore, reference lists of main reports and review articles were also reviewed manually to identify additional relevant publications.

2.2. Selection Criteria {#sec2.2}
-----------------------

The following criteria were used to select eligible studies for further meta-analysis: (1) case-control design; (2) full-text study; (3) studies that evaluated the associations between miRNA polymorphisms and CRC risk; and (4) studies that included detailed genotyping data.

2.3. Data Extraction {#sec2.3}
--------------------

Articles were reviewed independently by two reviewers and data with discrepancies were discussed by all authors. For each included study, the following information was collected: first author, year of publication, country of origin, ethnicity, source of control, total number of cases and controls, and genotyping methods as well as number of cases and controls with the different genotypes. Different ethnic groups were categorized as Caucasian, Asian, African, and "mixed." All the case and control groups were well controlled.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The associations between miRNA polymorphisms and CRC risk were measured by odds ratio (OR) with 95% confidence interval (CI). The significance of the pooled OR was determined by the *Z* test.

The meta-analysis assessed association by using 5 different genetic models: homozygous genetic model, heterozygote genetic model, dominant genetic model, recessive genetic model, and allelic model. Hardy-Weinberg equilibrium (HWE) among the control subjects was tested by the Chi-square test. Statistical heterogeneity among studies was assessed with the *Q* and *I* ^2^ statistics. If the *P* value of heterogeneity test was more than 0.05 (*P* \> 0.05), the pooled OR estimate of the study was calculated by the fixed-effects model. Otherwise, the random-effects model was used. The value of the *I* index was used to assess the degree of heterogeneity (*I* ^2^ \< 25%: no heterogeneity; 25% \< *I* ^2^ \< 50%: moderate heterogeneity; 50% \< *I* ^2^ \< 75%: high heterogeneity; and *I* ^2^ \> 75%: extreme high heterogeneity). Publication bias was evaluated by the funnel plot. All statistical analyses were carried out with the review manager version 5.1 (Revman; The Cochrane Collaboration, Oxford, UK).

3. Results {#sec3}
==========

3.1. Characteristics of Studies {#sec3.1}
-------------------------------

According to the inclusion criteria defined above ([Figure 1](#fig1){ref-type="fig"}), fifteen studies on miRNA polymorphisms with CRC risk were identified \[[@B8]\], including 5,486 CRC patients and 7,184 cancer-free controls. All the included eligible studies were published in English or Chinese. Among the eligible fifteen studies, eleven studies were based on Asian backgrounds which were carried out in China and Korea. Only four studies were based on Caucasian, having been carried out in Greek, Lithuania, Italy, and Czech, respectively. Simultaneously, there were seven hospital based studies and eight population based studies. Main characteristics of the included studies were listed in [Table 1](#tab1){ref-type="table"}.

3.2. Meta-Analysis Results {#sec3.2}
--------------------------

As shown in [Table 2](#tab2){ref-type="table"}, the frequencies of the minor allele varied widely across the eligible studies, ranging from 0.14 to 0.80 (rs2910164), 0.33 to 0.82 (rs2292832), 0.34 to 0.66 (rs11614913), and 0.14 to 0.68 (rs3746444). The average frequencies of the minor allele in the four polymorphisms were 0.47, 0.66, 0.51, and 0.27, respectively. The distributions of genotypes in the controls were all in agreement with HWE except four studies \[[@B8], [@B24]--[@B26]\].

The main results of this meta-analysis were presented in Table S1, in Supplementary Material available online at <http://dx.doi.org/10.1155/2015/276410>. There were 11 studies with 3,937 cases and 5,120 controls for rs2910164. miR-146a rs2910164 polymorphism has no association with CRC risk in the overall population (C versus G: OR = 0.96, 95% CI = 0.82--1.12, *P* = 0.62, [Figure 2](#fig2){ref-type="fig"}; CC versus GG: OR = 1.02, 95% CI = 0.78--1.33, *P* = 0.89; GC versus GG: OR = 1.00, 95% CI = 0.83--1.20, *P* = 0.97; CC versus GG + GC: OR = 1.03, 95% CI = 0.80--1.31, *P* = 0.83; GC + CC versus GG: OR = 1.01, 95% CI = 0.84--1.22, *P* = 0.89). After omitting the study which was not according with the HWE, the results were in accordance with the overall population (C versus G: OR = 0.93, 95% CI = 0.79--1.09, *P* = 0.38; CC versus GG: OR = 0.97, 95% CI = 0.73--1.28, *P* = 0.83; GC versus GG: OR = 0.98, 95% CI = 0.81--1.20, *P* = 0.88; CC versus GG + GC: OR = 0.99, 95% CI = 0.76--1.27, *P* = 0.91; GC + CC versus GG: OR = 0.99, 95% CI = 0.82--1.20, *P* = 0.90). When stratifying analysis by ethnicity, there was also no significant association observed between the rs2910164 and CRC susceptibility in the five genetic models. In the analysis stratified by the source of control, significant associations were observed in the hospital based studies for recessive genetic model (CC versus GG + GC: OR = 1.24, 95% CI = 1.03--1.49, *P* = 0.02). No associations were found in population based studies.

The association of the rs2292832 polymorphism with CRC susceptibility was investigated in 5 studies with 1,568 cases and 1,824 controls. We failed to find any significant associations in any genotype (T versus C: OR = 1.05, 95% CI = 0.95--1.17, *P* = 0.36, [Figure 3](#fig3){ref-type="fig"}; TT versus CC: OR = 1.09 95% CI = 0.87--1.37, *P* = 0.44; CT versus CC: OR = 1.35, 95% CI = 0.64--2.86, *P* = 0.43; TT versus CC + CT: OR = 0.91, 95% CI = 0.54--1.53, *P* = 0.71; TT + CT versus CC: OR = 1.24, 95% CI = 0.82--1.87, *P* = 0.31). And there was also no association existing in any genetic models after we rejected the studies which were not in agreement with HWE. There was only one study based on Caucasian. When excluding the Caucasian study, the null association remained in Asians. We further made stratified analysis based on the source of control. And we observed significant associations in population based studies in the recessive genetic model (TT versus CC + CT: OR = 1.18, 95% CI = 1.08--1.38, *P* = 0.04).

Ten studies with 2,906 cases and 4,150 controls were used to evaluate the relationship between rs11614913 polymorphism and CRC risk. No significant association was detected under all the genetic models (haploid model: OR = 1.10, 95% CI = 0.84--1.43, *P* = 0.50; homozygote comparison: OR = 1.18, 95% CI = 0.76--1.83, *P* = 0.47; heterozygote comparison: OR = 1.11, 95% CI = 0.82--1.50, *P* = 0.49; dominant model: OR = 1.13, 95% CI = 0.83--1.55, *P* = 0.44 and recessive model: OR = 1.07, 95% CI = 0.82--1.38, *P* = 0.63, [Figure 4](#fig4){ref-type="fig"}). When excluding the studies which were inconsistent with HWE, the results showed a significant association between rs11614913 polymorphism and CRC risk in the homozygous genetic model (TT versus CC: OR = 0.80, 95% CI = 0.68--0.95, *P* = 0.009). Further subgroup analysis by ethnicity showed no association between rs11614913 and CRC risk either in Caucasians or in Asians. And no significant associations were observed in population based studies and hospital based studies for all genetic models.

For miR-499 rs3746444 polymorphism, our meta-analysis contained 6 studies with 1,471 cases and 2,104 controls. Overall, the rs3746444 polymorphism has no association with CRC risk (haploid model: OR = 0.96, 95% CI = 0.84--1.10, *P* = 0.58; homozygote comparison: OR = 0.90, 95% CI = 0.67--1.22, *P* = 0.50; heterozygote comparison: OR = 0.83, 95% CI = 0.54--1.26, *P* = 0.38; dominant model: OR = 0.91, 95% CI = 0.71--1.17, *P* = 0.45 and recessive model: OR = 0.95, 95% CI = 0.73--1.25, *P* = 0.73). Further analysis of the studies which were in agreement with HWE also showed no association between the rs3746444 polymorphism and CRC. And null associations were found in hospital based studies or population based studies. However, in the stratified analysis according to ethnicity, the homozygote model demonstrated a significant decrease in the CRC risk in Caucasians (GG versus AA: OR = 0.57, 95% CI = 0.34--0.95, *P* = 0.03, [Figure 5](#fig5){ref-type="fig"}).

3.3. Publication Bias {#sec3.3}
---------------------

In this meta-analysis, we performed funnel plot to access the publication bias. As showed in [Figure 6](#fig6){ref-type="fig"}, the funnel plots failed to reveal any obvious asymmetry in all genotypes in overall population. Therefore, the results indicated that publication bias was not significant in this meta-analysis.

4. Discussion {#sec4}
=============

Allelic variants in the sequence of mature miRNAs represent a particularly interesting potential source of phenotypic diversity of genetic diseases, which may contribute directly to disease susceptibility \[[@B36]\]. Accumulating evidence has shown that miRNAs regulate the expression of roughly 30% of the all human genes through posttranscriptional mechanisms \[[@B37]\]. SNPs in miRNA genes could function through three ways: firstly, the transcription of the primary transcript; secondly, pri-miRNA and pre-miRNA processing; and thirdly, effects on miRNA-mRNA interactions \[[@B7]\]. Genetic effects connected to SNPs at the level of miRNA genes may have a significant relationship with the expression and clinical features in CRC \[[@B25]\].

A large number of studies had highlighted several associations between SNPs in miRNAs and the risk of CRC \[[@B8]\]. However, controversial experimental data were obtained. For example, there was no significant association between rs2910164 and CRC in Hezova et al.\'s study \[[@B27]\], whereas Chae et al. reported that miR-146a rs2910164 polymorphism of genotype CC may contribute to a higher risk of CRC \[[@B31]\]. Min et al. from Korea \[[@B28]\] demonstrated that miR-196a2 rs11614913 polymorphism had a decreased risk to CRC, whereas Lv et al. \[[@B8]\] reported that T allele in rs11614913 was associated with an increased risk of CRC compared with the C allele.

The present meta-analysis, including 5,486 CRC patients and 7,184 cancer-free controls from 15 case-control studies, was conducted to evaluate the association between the four common SNPs in miRNAs (miR-146a rs2910164, miR-149 rs2292832, miR-196a2 rs11614913, and miR-499 rs3746444) and CRC risk. In this study, we found that rs3746444 polymorphism has no association with CRC risk in the overall population. However, accumulative data from two studies based on Caucasian background (317 cases and 477 controls) showed significantly decreased cancer risks in the homozygous model. Considering the limited sample size, we need more large well-designed studies to evaluate the result. Simultaneously, we failed to find any significant correlation between the rs2910164, rs2292832, and rs11614913 polymorphisms and risk of CRC in overall studies or in different ethnic groups for all genetic models. But significant association between rs2910164 and CRC was observed in hospital based studies in the recessive model. And we found that rs2292832 polymorphisms may be associated with increased the risk of CRC in population based studies for recessive model. While T allele of rs11614913 was a protect factor of CRC in the homozygous model when we excluded the studies which were not in agreement with HWE.

Although the biological mechanism of SNPs in miRNAs contributing to the regulation of cancer susceptibility and development remains unknown, a large quantity of meta-analyses has been engaged in the newly developed field in the past few years \[[@B38]\]. A previous meta-analysis by K. Srivastava and A. Srivastava \[[@B38]\] was demonstrated that miR-196a2 rs11614913 polymorphisms have significant associations with overall cancer risk. In Xu et al.\'s meta-analysis \[[@B39]\], TT genotype of rs11614913 polymorphism was associated with decreased cancer risk. Rs2910164 C allele was associated with decreased overall cancer risk especially for cervical cancer and prostate cancer risk in Chinese population. Rs3746444 G allele was a risk factor in Chinese population, especially for breast cancer. Different results were also presented in several meta-analyses which evaluated the relationship between miRNAs and CRC risk \[[@B40]\]. Wan et al.\'s study demonstrates that miR-196a2 rs11614913 most likely contributes to decreased risk of CRC, whereas miR-146a rs2910164 may not be associated with the susceptibility to CRC \[[@B40]\]. While the pooled data from Du et al.\'s meta-analysis supported that the miR-196a2 rs11614913 and miR-149 rs2292832 polymorphisms may contribute to susceptibility to CRC \[[@B41]\]. The latest meta-analysis, which related to the associations between miRNA polymorphisms and colorectal cancer, performed by Wu et al. indicated that SNP rs11614913 but not SNP rs2910164 and SNP rs2292832 may contribute to susceptibility to CRC in an Asian-specific manner \[[@B42]\]. This result was unconformable with our results. Compared with Wu\'s meta-analysis which included 9 relevant studies, our research totally identified 15 studies including 5,486 CRC cases and 7,184 controls. Thus, our meta-analysis contained the newest data and largest sample size on the study of the relationship between miRNAs and colorectal cancer. Additionally, we performed subgroup analyses by different data information in more detail.

Some limitations still existed in this meta-analysis. Firstly, the included studies are mainly based on Asian background. There were only five studies based on Caucasian background and no studies on African background. Secondly, some detailed information (such as sex, age, life-style, and environmental factors) was not considered. Further large scale multicenter studies based on Caucasian or African will be needed to clarify the possible roles of these polymorphisms in CRC. Though many investigators have been devoted to identify the roles of the miRNAs in carcinogenesis, the mechanisms were still unclear. Further biologically functional studies are warranted to explain the molecular mechanisms.

In summary, this meta-analysis showed that there were no associations between the four polymorphisms and CRC risk in the overall population. Further analysis stratified by the source of control showed that rs2910164 polymorphism is associated with CRC risk in hospital based studies, and rs2292832 polymorphism may contribute to the susceptibility of CRC in population based studies. In the pooled analysis from all studies which are in agreement with HWE revealed that rs11614913 TT carriers may have a decreased CRC risk. Moreover, in the stratified analysis according to ethnicity, rs3746444 polymorphism may reduce the risk of CRC in Caucasians.
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![Flow chart of study selection.](BMRI2015-276410.001){#fig1}

![Forest plot of miR-146a rs2910164 polymorphism and CRC risk (C versus G). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](BMRI2015-276410.002){#fig2}

![Forest plot of miR-149 rs2292832 polymorphism and CRC risk (T versus C). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](BMRI2015-276410.003){#fig3}

![Forest plot of miR-196a2 rs11614913 polymorphism and CRC risk (TT versus CC + CT). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](BMRI2015-276410.004){#fig4}

![Forest plot of miR-499 rs3746444 polymorphism and CRC risk (GG versus AA). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](BMRI2015-276410.005){#fig5}

![Funnel plot assessing evidence of publication bias from the eligible studies. (a) miR-146a rs2910164; (b) miR-149 rs2292832; (c) miR-196a2 rs11614913; (d) miR-499 rs3746444.](BMRI2015-276410.006){#fig6}

###### 

Characteristics of the studies included in the meta-analysis.

  First author            Year   Country             Ethnicity   Genotyping method   Source of control   Number (case/control)   SNP number
  ----------------------- ------ ------------------- ----------- ------------------- ------------------- ----------------------- ------------
  Dikaiakos \[[@B22]\]    2015   Greek               Caucasian   PCR-RFLP            HB                  157/299                 1, 3, 4
  Kupcinskas \[[@B29]\]   2014   Lithuania, Latvia   Caucasian   TaqMan              HB                  193/428                 1, 3
  Mao \[[@B23]\]          2014   China               Asian       SNPScan             PB                  554/566                 1
  Hu \[[@B30]\]           2014   China               Asian       PCR-RFLP            HB                  276/373                 1, 4
  Wu \[[@B24]\]           2014   China               Asian       ASA                 HB                  175/300                 1, 2, 4
  Lv \[[@B8]\]            2013   China               Asian       PCR-RFLP            PB                  353/540                 1, 2, 3, 4
  Chae \[[@B31]\]         2013   Korea               Asian       PCR-RFLP            PB                  399/568                 1
  Ma \[[@B32]\]           2013   China               Asian       TaqMan              PB                  1147/1203               1
  Vinci \[[@B25]\]        2013   Italy               Caucasian   TaqMan              HB                  160/178                 1, 2, 3, 4
  Zhang \[[@B26]\]        2012   China               Asian       PCR-RFLP            PB                  478/477                 2, 3
  Hezova \[[@B27]\]       2012   Czech               Caucasian   TaqMan              HB                  197/212                 1, 3
  Min \[[@B28]\]          2012   Korea               Asian       PCR-RFLP            PB                  446/502                 1, 2, 3, 4
  Zhu \[[@B33]\]          2012   China               Asian       TaqMan              PB                  573/588                 3
  Chen \[[@B34]\]         2012   China               Asian       PCR-LDR             HB                  126/407                 3
  Zhan \[[@B35]\]         2011   China               Asian       PCR-RFLP            PB                  252/543                 3

HWE: Hardy-Weinberg equilibrium; PB: population based; HB: hospital based; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; LDR: ligation detection reaction; ASA: allele-specific amplification; SNP: single-nucleotide polymorphisms; SNP number 1: miR-146-a G\>C (rs2910164); 2: miR-149 C\>T (rs2292832); 3: miR-196a-2 C\>T (rs11614913); 4: miR-499 A\>G (rs3746444).

###### 

MiRNA polymorphisms genotype distribution and allele frequency in cases and controls.

  First author                 Genotype (*N*)   Allele frequency (*N*)                                                                         
  ---------------------------- ---------------- ------------------------ ----- ----- ------ ----- ----- ----- ------ ----- ------ ----- ------ -------------
  rs2910164                                                                                                                                    
  Dikaiakos 2015 \[[@B22]\]    157              8                        48    101   299    21    120   158   64     250   162    436   0.80   0.782
  Kupcinskas 2014 \[[@B29]\]   193              140                      50    2     428    275   134   15    330    54    684    164   0.14   0.789
  Mao 2014 \[[@B23]\]          554              70                       291   186   566    85    271   205   431    663   441    681   0.61   0.768
  Hu 2014 \[[@B30]\]           200              34                       82    84    373    44    187   142   250    150   275    471   0.38   0.137
  Wu 2014 \[[@B24]\]           175              22                       59    80    300    53    120   114   103    219   226    348   0.68   **0.035**
  Lv 2013 \[[@B8]\]            331              54                       230   47    513    96    274   143   338    324   560    466   0.49   0.080
  Chae 2013 \[[@B31]\]         399              61                       182   156   568    121   282   165   304    494   524    612   0.62   0.980
  Ma 2013 \[[@B18]\]           1147             444                      534   169   1203   397   614   192   1422   872   1408   998   0.38   0.075
  Vinci 2013 \[[@B25]\]        160              17                       57    86    178    13    65    100   91     229   91     265   0.72   0.590
  Hezova 2012 \[[@B27]\]       197              115                      70    12    212    124   79    9     300    94    327    97    0.24   0.415
  Min 2012 \[[@B28]\]          446              151                      233   62    502    188   245   69    535    357   621    383   0.40   0.443
                                                                                                                                               
  rs2292832                                                                                                                                    
  Wu 2014 \[[@B24]\]           175              21                       123   28    300    76    58    116   165    179   210    290   0.52   **\<0.001**
  Lv 2013 \[[@B8]\]            347              30                       64    253   459    48    103   308   124    570   199    719   0.82   **\<0.001**
  Vinci 2013 \[[@B25]\]        160              79                       58    23    178    86    75    17    216    104   247    109   0.33   0.912
  Zhang 2012 \[[@B15]\]        443              50                       190   203   435    46    202   187   290    596   294    576   0.67   0.431
  Min 2012 \[[@B28]\]          446              48                       177   221   502    51    219   232   273    619   321    683   0.69   0.948
                                                                                                                                               
  rs11614913                                                                                                                                   
  Dikaiakos 2015 \[[@B22]\]    157              19                       69    69    299    33    149   117   107    207   215    383   0.66   0.156
  Kupcinskas 2014 \[[@B29]\]   193              79                       87    27    428    199   174   54    245    141   572    282   0.37   0.104
  Lv 2013 \[[@B8]\]            374              10                       223   114   531    109   331   91    243    451   549    413   0.60   **\<0.001**
  Vinci 2013 \[[@B25]\]        160              62                       86    12    178    83    84    11    210    110   250    106   0.34   0.087
  Hezova 2012 \[[@B27]\]       197              82                       89    26    212    87    103   22    253    141   277    147   0.36   0.291
  Zhang 2012 \[[@B15]\]        455              79                       204   172   463    81    197   185   362    548   359    567   0.60   **0.026**
  Min 2012 \[[@B28]\]          466              120                      201   125   502    100   254   148   441    451   454    550   0.48   0.633
  Zhu 2012 \[[@B33]\]          573              140                      303   130   588    121   295   172   583    563   537    639   0.49   0.790
  Chen 2012 \[[@B34]\]         126              27                       64    35    407    94    206   107   118    134   394    420   0.53   0.788
  Zhan 2011 \[[@B35]\]         252              68                       128   56    543    112   267   163   264    240   493    593   0.48   0.890
                                                                                                                                               
  rs3746444                                                                                                                                    
  Dikaiakos 2015 \[[@B22]\]    157              85                       64    8     299    182   99    18    234    80    463    135   0.25   0.361
  Hu 2014 \[[@B30]\]           211              157                      49    5     373    282   81    10    363    59    654    101   0.14   0.162
  Wu 2014 \[[@B24]\]           175              96                       17    38    300    141   44    63    209    93    326    170   0.31   **\<0.001**
  Lv 2013 \[[@B8]\]            346              258                      88    504   366    138                            ---    ---          
  Vinci 2013 \[[@B25]\]        160              35                       32    93    178    17    56    105   102    218   90     266   0.68   **0.026**
  Min 2012 \[[@B28]\]          446              292                      142   12    502    334   154   14    726    166   822    182   0.19   0.453

A: the major allele; a: the minor allele; MAF: minor allele frequencies.
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